49 scheduled presentations will explore
several types of cancer, as well as the next frontier of health
equity
NEW
BRUNSWICK, N.J., May 23, 2024
/PRNewswire/ -- Clinicians and scientists from Rutgers Cancer
Institute and RWJBarnabas Health will lead sessions and present
their latest discoveries from their innovative cancer research
program at the 2024 American Society of Clinical Oncology (ASCO)
Annual Meeting, to be held in Chicago (and online) from May 30-June 4. A total of 49 accepted abstracts
and presentations will cover cutting-edge topics, including two
oral sessions highlighting the National Surgical Quality
Improvement Program (NSQIP) audit of enhanced recovery after
surgery protocols for radical cystectomy, as well as social
vulnerability and clinical trial enrollment's role in the next
frontier of health equity.
"Our world-renowned integrated network of researchers and
clinicians at Rutgers Cancer Institute and RWJBarnabas Health
continues to innovate and investigate strategies that will achieve
the best possible outcomes for our patients. This is reflected in
the dynamic lineup of presentations featured at the 2024 ASCO
Annual Meeting, underscoring our team's commitment and dedication,"
said Steven K. Libutti, MD, FACS,
Director, Rutgers Cancer Institute and Senior Vice President,
Oncology Services, RWJBarnabas Health. "As New Jersey's only
National Cancer Institute-designated Comprehensive Cancer Center
and the leading cancer program in the state, we are at the
forefront of advancing cancer research and care to conquer a
disease that impacts so many. We look forward to sharing our array
of recent advancements and findings at this year's meeting."
The research accepted for presentation at ASCO includes one
late-breaking abstract, oral and poster sessions as well as
publication-only abstracts highlighting data in numerous types of
cancer, including breast, colorectal, lymphoma, and lung.
Highlights of the accepted abstracts include the following:
- Findings from a study that assesses how social vulnerability
impacts clinical trial enrollment and explores the interaction
between race and social vulnerability among patients with one of
the top five cancers - breast, prostate, lung, colorectal and
pancreas. Findings confirm that neighborhood social vulnerability
is a barrier to trial enrollment, even more so among Black
patients.
- Utilization of enhanced recovery after surgery (ERAS) protocols
for radical cystectomy has been associated with improved
postoperative recovery and shorter hospital stays. This study was
designed to assess the impact of increasing compliance to ERAS
components on postoperative outcomes in patients who underwent
radical cystectomy. Researchers reviewed 3,708 patients from the
National Surgical Quality Improvement Program database who
underwent radical cystectomy from 2019 – 2021.
- Updates from CTEP 10492, a Phase 1/1b study investigating the AKT inhibitor
ipatasertib with chemoradiation to treat locally advanced head and
neck squamous cell carcinoma (HNSCC). The primary objective of this
study is to determine the maximum tolerated dose and recommended
Phase 2 dose of ipatasertib in combination with definitive
chemoradiation therapy (CRT) in locally advanced HNSCC based on
dose-limiting toxicities. This phase 1/1b study will be the first to establish safety
and preliminary efficacy of ipatasertib combined with standard of
care definitive CRT for HNSCC.
- Data from a Phase 3 clinical trial evaluates the efficacy and
safety of odronextamab plus CHOP vs rituximab plus CHOP in
previously untreated diffuse large B-cell lymphoma (DLBCL)
patients. OLYMPIA-3 is a Phase 3,
randomized, open-label, multicenter study of O-CHOP vs. R-CHOP in
patients with previously untreated DLBCL and intermediate- or
high-risk features. The primary endpoints of the study are the
incidence of dose-limiting toxicities, and incidence and severity
of treatment-emergent adverse events as well as progression-free
survival by independent central review.
- CIPHER (NCT05333874), a single institution pilot study,
evaluated whether trend of circulating tumor DNA (ctDNA) testing
during neoadjuvant therapy (NAT) can serve as an early indicator of
treatment response and inform disease management in the adjuvant
setting. The study included 35 patients with stage II-III triple
negative and HER2+ breast cancer and longitudinal ctDNA testing
performed during standard of care NAT.
The full list of presentations at this year's 2024 American
Society of Clinical Oncology Annual Meeting can be found here.
About Rutgers Cancer Institute
As New Jersey's only National Cancer
Institute-designated Comprehensive Cancer Center,
Rutgers Cancer Institute, together with RWJBarnabas Health,
offers the most advanced cancer treatment options, including bone
marrow transplantation, proton therapy, CAR T-cell therapy and
complex surgical procedures. Along with clinical trials and novel
therapeutics such as precision medicine and immunotherapy –
many of which are not widely available – patients have access to
these cutting-edge therapies at Rutgers Cancer Institute in
New Brunswick, Rutgers
Cancer Institute at University Hospital in Newark, as well as through RWJBarnabas
Health facilities.
For journalists – contact:
Krista Didzbalis
Corporate Communications Specialist, Strategic Communications,
RWJBarnabas Health
732.507.8307
krista.didzbalis2@rwjbh.org
For patient appointments/inquiries – contact:
844-CANCERNJ (844-226-2376)
View original content to download
multimedia:https://www.prnewswire.com/news-releases/rutgers-cancer-institute-and-rwjbarnabas-health-set-to-unveil-extensive-new-cancer-research-findings-at-2024-asco-annual-meeting-302154815.html
SOURCE Rutgers Cancer Institute and RWJBarnabas Health